Yanjun Mi

机构：China West Normal University, Chinese Academy of Sciences, First Affiliated Hospital of Xiamen University, Institute of Atmospheric Physics, University of Chinese Academy of Sciences · ORCID：0000-0002-8164-6414

发表论文 68 篇 · 总被引 1485 次 · h-index 22

代表论文

• Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials (2025 · Nature Medicine · 被引 48)
• Ferroptosis in cancer: revealing the multifaceted functions of mitochondria (2025 · Cellular and Molecular Life Sciences · 被引 47)
• SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study. (2023 · Journal of Clinical Oncology · 被引 32)
• Abstract CT247: Updated efficacy and safety of anti-TROP2 ADC SKB264 (MK-2870) for previously treated advanced NSCLC in Phase 2 study (2024 · Cancer Research · 被引 19)
• Abstract CT038: Preliminary efficacy and safety results of anti-TROP2 ADC SKB264 (MK-2870) in patients (pts) with previously treated advanced gastric (G) or gastroesophageal junction (GEJ) cancer from a Phase 2 study (2024 · Cancer Research · 被引 19)
• FAP-targeted PET/CT imaging in patients with breast cancer from a prospective bi-center study: insights into diagnosis and clinic management (2025 · European Journal of Nuclear Medicine and Molecular Imaging · 被引 12)